IDEAYA Biosciences (NASDAQ:IDYA) Now Covered by Analysts at Stephens

Stephens started coverage on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note issued to investors on Monday, MarketBeat.com reports. The firm issued an overweight rating and a $51.00 price objective on the stock.

Several other research firms also recently commented on IDYA. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald began coverage on shares of IDEAYA Biosciences in a research note on Tuesday, October 15th. They set an “overweight” rating on the stock. JPMorgan Chase & Co. decreased their target price on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Citigroup decreased their target price on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Finally, Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $53.67.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $25.54 on Monday. IDEAYA Biosciences has a 1 year low of $25.35 and a 1 year high of $47.74. The firm has a market cap of $2.21 billion, a PE ratio of -10.96 and a beta of 0.86. The company has a 50 day simple moving average of $30.79 and a two-hundred day simple moving average of $36.00.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the company earned ($0.46) EPS. As a group, research analysts anticipate that IDEAYA Biosciences will post -2.46 earnings per share for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of hedge funds have recently bought and sold shares of IDYA. SG Americas Securities LLC bought a new position in IDEAYA Biosciences in the 1st quarter worth about $101,000. ProShare Advisors LLC boosted its stake in IDEAYA Biosciences by 21.1% in the 1st quarter. ProShare Advisors LLC now owns 17,047 shares of the company’s stock worth $748,000 after purchasing an additional 2,966 shares in the last quarter. Orion Portfolio Solutions LLC bought a new position in IDEAYA Biosciences in the 1st quarter worth about $1,431,000. Vanguard Group Inc. boosted its stake in IDEAYA Biosciences by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock worth $182,355,000 after purchasing an additional 679,985 shares in the last quarter. Finally, Covestor Ltd boosted its stake in IDEAYA Biosciences by 9,225.0% in the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after purchasing an additional 1,107 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.